Benpine

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Benpine

The Identity of Benpine: Definition and Drug Classification

Benpine is a synthetic, prescription-only medication whose active component is Chlordiazepoxide, belonging to the pharmacological class of benzodiazepines. The medication functions as a Central Nervous System (CNS) depressant, slowing nerve activity within the central nervous system. Chlordiazepoxide is a long-acting agent in its class, possessing a characteristic chemical structure derived from the 1,4-Benzodiazepine scaffold. Its status as a foundational benzodiazepine is defined by its specific binding affinity within the CNS, making it recognized for its stabilizing properties.

Composition, Origin, and Available Forms

Benpine is a single active ingredient product containing only Chlordiazepoxide, a purely synthetic compound developed for medical use. The drug is supplied for both oral and parenteral routes of administration. The medication is available to patients as solid capsules for ingestion and as a solution for deep intramuscular injection for use when stabilization of intense conditions is required. Chlordiazepoxide is structurally and functionally related to other long-acting agents within the same class. This sustained characteristic differentiates it from compounds with shorter half-lives, influencing its utility in various management contexts.

Core Therapeutic Role and General Effect

The fundamental purpose of Benpine is to serve as an anxiolytic agent, stabilizing and calming the nervous system. Its mechanism involves the substance acting as a modulator of the brain's main inhibitory system, which uses the neurotransmitter GABA (gamma-aminobutyric acid). This action promotes neural inhibition, which relieves states of excessive internal distress and physical tension. The drug’s capacity to reduce excitability provides the basis for its utility as a systemic stabilizing and relaxing agent, typically employed in situations requiring the mitigation of acute overstimulation.

Regulatory References

  1. NIH MedlinePlus Drug Information on Chlordiazepoxide

What side effects are possible with Benpine?

Possible Side Effects and Safety Information

The official safety profile for Benpine (Chlordiazepoxide) is structured by the expected central nervous system (CNS) effects and critical warnings documented by regulatory authorities like the FDA and EMA.


Adverse Reaction Scope

Adverse reactions are officially categorized by frequency and system involvement:

  • Common Reactions: The most frequently reported effects are related to CNS depression, including drowsiness (somnolence), ataxia (difficulty with coordination), and confusion. These effects are generally noted to be controllable with a reduction in the prescribed dosage.

  • Infrequent or Occasionally Reported: Less common reactions documented in regulatory sources include gastrointestinal issues (such as nausea and constipation), skin eruptions, edema, minor menstrual irregularities, and changes in libido. Rarely, paradoxical reactions like excitement or acute rage have been observed.


Serious Safety Considerations

The official prescribing information includes several critical safety warnings:

  • Risk of Dependence and Misuse: Benpine carries an official Black Box Warning due to the significant risk of abuse, misuse, addiction, and physical dependence, which increases with longer treatment duration and higher daily dose.
  • Interaction with Opioids: Another Black Box Warning is in place regarding the risk of profound sedation, respiratory depression, coma, and death when Benpine is used concurrently with opioids or other CNS depressants.
  • Systemic Concerns: Serious, occasionally reported reactions include blood dyscrasias (e.g., Agranulocytosis) and hepatic dysfunction (jaundice), necessitating periodic monitoring during prolonged therapy.

Population-Specific Notes

Older and debilitated patients are noted to be more susceptible to common CNS depressant effects. Caution and close supervision are necessary for individuals with documented hepatic or renal impairment. Official labeling also suggests a potential risk of congenital malformations if the medicine is used during the first trimester of pregnancy.

Overdose and Emergency Response

Overdose and When to Seek Help

Overdosage with Benpine (Chlordiazepoxide) results in a progressive state of Central Nervous System (CNS) depression. Documented manifestations listed in official regulatory labeling include somnolence, confusion, stupor, ataxia (loss of coordination), and diminished reflexes. Hypotension (low blood pressure) is a possible physiological sign.

Classification Official Regulatory Documentation
Severity Classification Manifestations range from mild CNS depression to life-threatening outcomes, particularly respiratory depression and death with co-ingestants.
Documented Outcomes Profound sedation, respiratory depression, and coma.

Immediate medical attention is required for any suspected overdose. Official guidance mandates seeking help right away by calling emergency services or going to the nearest hospital emergency room.

Treatment is based on general supportive measures. These measures, which are detailed in regulatory documents, include maintaining an adequate airway, administering intravenous fluids, and continuous monitoring of respiration, pulse, and blood pressure. Management procedures may involve immediate gastric lavage, and treating hypotension with agents like levarterenol. While the antagonist Flumazenil exists, regulatory warnings advise caution as its use risks precipitating life-threatening seizures. Special consideration is noted for the elderly and debilitated due to their increased susceptibility to oversedation and ataxia.

Therapeutic Uses of Benpine

Benpine (Chlordiazepoxide) may be part of symptomatic management applied across domains where additional symptomatic support is needed. The medication is commonly used to help with conditions characterized by anxiety disorders, to provide short-term relief of anxiety symptoms, and to assist in managing the withdrawal symptoms of acute alcoholism. This medication is generally used to address symptom clusters that may become intense or disruptive, particularly those involving emotional distress and heightened physical tension. This approach provides support that helps ease the overall symptom burden, and contributes to improved day-to-day comfort during periods when symptoms interfere with daily functioning.

“The drug's role is relevant for stabilizing symptoms associated with heightened physiological activity and severe psychological or physical strain.”

The therapeutic domains play a role in managing core psychological manifestations like worry, nervousness, and apprehension, alongside physical symptoms like agitation and tremors. It is applied when appropriate in clinical scenarios such as preoperative apprehension and anxiety or when managing associated muscle tension.


Quick Fact: Support for Intense Agitation The drug plays a role in managing severe symptoms of acute withdrawal, which assists with maintaining functional stability during phases of heightened distress.

Eligibility and Restrictions for Use

Who can and cannot use Benpine? — Official Regulatory Information

Eligibility Scope

Populations for whom use is allowed (as stated in label): Adult patients and pediatric patients aged 6 years and older have established use.

Populations for whom use is not recommended (if applicable): Use is not recommended for children younger than 6 years, as safety and efficacy have not been established. The medicine is not recommended for women who are breastfeeding.

Populations for whom use is contraindicated: Benpine is contraindicated in patients with a known hypersensitivity to benzodiazepines, as well as in those with Myasthenia gravis, Severe Hepatic Insufficiency, Severe Pulmonary Insufficiency, Respiratory Depression, or Sleep apnoea syndrome.

Age and Condition-Specific Eligibility Rules

Children under 6 years are not recommended. Older adults require caution and a lower initial amount due to increased sensitivity. Caution is mandatory for patients with impaired renal or non-severe hepatic function, and for those with a history of alcohol or drug abuse, where careful surveillance is required.

Pregnancy and Lactation Eligibility Status: Use during pregnancy, particularly the first trimester, should almost always be avoided. Use during lactation is not recommended.

Connection to the overall eligibility profile: Official regulatory labels define who can and cannot use Benpine by establishing a clear structure of exclusions and constraints. The profile mandates absolute contraindications for severe systemic diseases, defines not established status for the pediatric population under age six, and stipulates caution for older adults and patients with hepatic or renal impairment.

What should I know about interactions with other medicines?

Interactions with other medicines and products

The interaction profile of Benpine (Chlordiazepoxide) is defined by two primary documented mechanisms: Pharmacodynamic Potentiation and Pharmacokinetic Clearance Modification.

Pharmacodynamic Interactions and Restrictions

Co-administration with other substances that depress the central nervous system (CNS) results in the enhancement of central depressive effects, which can lead to increased sedation and respiratory complications.

  • Opioids and Alcohol: Concomitant use with opioid analgesics is associated with a severe regulatory risk, necessitating a Boxed Warning due to the potential for profound sedation, respiratory depression, coma, and death. Intake of alcohol must be avoided as it significantly enhances these central depressive effects.
  • Other CNS Depressants: This category includes antipsychotics, antidepressants, hypnotics, and barbiturates. The combination increases the overall sedative burden.
  • Formal Restrictions: The regulatory labeling for Chlordiazepoxide restricts its use with 4-hydroxybutanoic acid (Sodium oxybate), which is to be avoided.

Pharmacokinetic and Exposure Effects

Pharmacokinetic interactions primarily involve the hepatic clearance of Benpine. Substances that are Hepatic Enzyme Inhibitors (e.g., cimetidine, disulfiram) reduce the clearance of the benzodiazepine, which may potentiate its action and increase exposure. Conversely, Hepatic Enzyme Inducers (e.g., rifampicin) can increase clearance, potentially reducing Benpine's effect. Additionally, Benpine may increase the plasma levels of co-administered medicines such as Digoxin and Phenytoin.

Population-Specific Notes

Geriatric patients and individuals with hepatic impairment have an increased susceptibility to the additive CNS depressant effects and potentiated action due to slower clearance, respectively.

Mechanism of Action

The mechanism of Chlordiazepoxide (Benpine) centers on its action as a Positive Allosteric Modulator (PAM) of the GABA-A receptor complex, the primary mediator of inhibitory signaling in the Central Nervous System (CNS). The drug binds to a specific allosteric site on the receptor, not to activate it directly, but to increase the frequency of chloride ion ( Cl^-) channel opening when the endogenous neurotransmitter, GABA, is present. This molecular interaction initiates a key mechanistic cascade that leads to widespread CNS inhibition.

The resulting enhanced influx of negative chloride ions into the postsynaptic neuron causes hyperpolarization, effectively raising the cell's threshold for activation. This physiological dampening stabilizes neuronal signaling, particularly within the Limbic System and circuits associated with arousal. This targeted inhibition results in a generalized reduction of neuronal excitability and confers central skeletal muscle relaxing effects. The functional range of this mechanism is constrained by the availability of endogenous GABA, and prolonged presence may influence the receptor's responsiveness over time through receptor desensitization.

Dosage and Administration Information

Administration Scope

The administration of Benpine (Chlordiazepoxide) involves a specific route, frequency, and duration of use. The medication is primarily available for oral use as capsules, but it is also utilized as a solution for intramuscular (IM) injection when acute stabilization is required. Oral capsules may be taken with or without food, but must be swallowed whole with water and are not to be chewed.


Dosing and Frequency Patterns

Dosing Schedule: The standard regimen for anxiety involves administration 3 to 4 times daily. The strengths available are 5 mg, 10 mg, and 25 mg capsules. Doses for mild to moderate anxiety are typically 5 mg to 10 mg per administration, while severe anxiety requires doses of 20 mg or 25 mg, administered 3 to 4 times daily. In the management of acute alcohol withdrawal, an initial dose of 50 mg to 100 mg may be repeated as necessary, up to a maximum daily total of 300 mg.


Special Population and Procedural Conditions

Age-Group Administration Rules: Older adults or patients with debilitation start on a reduced regimen, typically 5 mg, 2 to 4 times daily, with an emphasis on using the smallest effective amount. Use is also indicated for pediatric patients aged 6 years and older, starting at 5 mg, 2 to 4 times daily. Treatment duration is limited to short-term use, often not exceeding four weeks, and the process includes a gradual reduction (tapering) of the dose when discontinuing the medication. The continued necessity for use is subject to periodic re-evaluation.


Connection to the Overall Use Protocol

The administration framework consists of a structured protocol defined by its dual delivery system (oral and IM) and specific numeric dose ranges for different conditions. This framework ensures that the medicine is administered in a measured, frequency-controlled manner, with a requirement for duration limits and a tapering sequence to govern its eventual cessation.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Benpine

This section provides a factual overview of the clinical research conducted on Benpine (Chlordiazepoxide), detailing the types of studies performed, the populations examined, and the stated limitations of the evidence, without offering medical advice or treatment recommendations.


Evidence for use in Anxiety Symptoms and Disorders

Benpine was studied for its role in research exploring anxiety symptoms and disorders through controlled clinical trials, including some older randomized studies. The research primarily focused on adults and, in some cases, pediatric patients aged 6 and older. These trials examined how symptoms change over time and used standardized rating scales to measure outcomes related to physical discomfort and episodic or acute changes. Studies reported how symptoms evolved in the observed populations over short intervals, with findings describing patterns observed in the measured study data over the immediate treatment period.

Evidence for use in Acute Alcohol Withdrawal

The role of Benpine in managing the conditions associated with acute alcohol withdrawal was evaluated in systematic reviews and controlled clinical trials. The primary focus of the research was on outcomes capturing phases of heightened symptom activity, such as reducing the overall severity of withdrawal symptoms, and monitoring the risk of developing severe complications like seizures or delirium tremens. The evidence base is recognized for the acute phase; studies reported that major complications were observed less frequently in treatment groups compared to control groups during detoxification.


Long-Term Studies and Follow-up Duration

Official regulatory documentation indicates that the core evidence base for Benpine is rooted in short-term studies, with the primary focus on research exploring acute or short-term symptom patterns. There is limited information for long-term outcomes related to the continuous or prolonged use of the medication. Long-term effects are not fully established, and research is ongoing regarding the sustained effects beyond the initial short treatment periods defined in the trials.

What is Still Uncertain About Benpine’s Evidence

The research base has several known limitations. The evidence quality varies across studies, particularly for older research that may not have used modern, standardized outcome measures. There is limited information for long-term outcomes, as the vast majority of efficacy evidence focuses on short-term investigation. Furthermore, the findings describe group patterns, not personal outcomes, and research does not determine whether an individual will respond similarly.

Key Studies & References

  1. Chlordiazepoxide - StatPearls - NCBI Bookshelf

Frequently Asked Questions (FAQ)

Common questions about Benpine (FAQ)

Q: Is Benpine used for anything besides the main condition?

According to official regulatory documents, Benpine is approved for several specific uses. These include the management of anxiety disorders, short-term relief of intense anxiety symptoms, the treatment of withdrawal symptoms of acute alcoholism, and addressing preoperative apprehension and anxiety.


Q: Which common pain relievers interact with Benpine?

Official information notes that Benpine has the potential to increase the effects of other substances that slow down the central nervous system. This is a particularly serious concern with opioid analgesics, where co-administration carries a Black Box Warning due to the risk of severe respiratory depression. Official information emphasizes the importance of informing the prescriber about all concurrent medications.


Q: Is Benpine considered a type of narcotic or controlled substance?

Yes, Benpine (Chlordiazepoxide) is classified as a Schedule IV controlled substance by the Drug Enforcement Administration (DEA). This regulatory classification is due to the potential for abuse, misuse, and physical dependence associated with the medication.


Q: Can Benpine affect my mood or sleep patterns?

Regulatory labeling indicates that Benpine can influence mental state and sleep. Reported effects include changes in mood such as depression or excitement, confusion, and rare paradoxical reactions like acute rage. Sleep disturbances are also noted as a possible side effect.


Q: How does Benpine differ from a standard over-the-counter medicine?

Benpine is designated as a prescription-only medication and is classified as a Schedule IV controlled substance. Unlike over-the-counter products, this regulatory status reflects the risks of abuse and dependence and the necessity of medical supervision due to its potential for serious drug interactions.


Q: Is the full effect of Benpine noticeable immediately or after time?

Benpine is a long-acting agent, and official pharmacokinetic information indicates that the full clinical effect may not be apparent immediately. The maximum concentration in the body and the full extent of the effect can be delayed for several hours after administration.


Q: Does Benpine lose effectiveness over time?

The official documentation states that the effectiveness of Benpine for continuous use longer than four months has not been assessed by systematic clinical studies. For this reason, official prescribing information notes that prescribers should periodically reassess the continued usefulness of the drug.


Q: Does Benpine treat the cause of the condition or just the symptoms?

Benpine works by enhancing the natural inhibitory signaling in the brain's central nervous system. Its primary role is to reduce excitability and provide relief from physical tension and symptoms of distress, rather than addressing the underlying cause of the condition.


Q: How does the effectiveness of Benpine compare across different age groups?

Regulatory information indicates that different age groups require specific dosing. Older adults and pediatric patients (aged 6 and older) are typically started on specific, often lower, doses. This is because older adults are known to be more susceptible to common central nervous system effects like drowsiness and confusion.


Q: What research is currently being done on Benpine?

Since the core evidence base for Benpine focuses on short-term use, official documentation states that its effectiveness for continuous use past four months has not been systematically assessed. This means that clinical surveillance and review of long-term effects is considered ongoing.


Q: How long does Benpine stay in your system?

Benpine and its active components undergo a prolonged elimination process. The parent drug has a half-life that can range from 5 to 30 hours, and its long-acting metabolites can persist in the body for several days after the medication is stopped.


Q: Can I take Benpine if I am also taking vitamins or supplements?

Official patient information highlights that individuals are asked to inform their prescriber about all concurrent medications, supplements, and vitamins. This measure supports the care team in assessing for potential additive effects or interactions between the substances.


Q: What happens if I miss a dose of Benpine?

Regulatory patient labeling provides instructions indicating that a missed dose is generally to be taken as soon as possible. The instructions describe skipping the missed dose and returning to the regular schedule if it is nearly time for the next scheduled dose. Official protocols state that double the prescribed amount is not to be taken.


Q: What if I experience a very rare side effect listed on the label?

Patient labeling and regulatory guidelines include statements describing when to consult with a prescriber immediately if any symptom is severe or concerning. They also describe when seeking urgent medical help or calling emergency services is necessary if a serious reaction occurs.


Q: Is there a generic version of Benpine available?

Yes, the active ingredient, Chlordiazepoxide Hydrochloride, is available in FDA-approved generic capsule formulations. These generic products are available in the same strengths as the brand-name product.


Q: What should I do if Benpine doesn't seem to be working?

The prescribing information notes that when a lack of desired effect occurs, the continued usefulness of the drug is subject to periodic reassessment by the prescriber. This is done on an individual patient basis.


Q: Can using Benpine affect laboratory test results?

Regulatory information notes that for individuals on extended therapy with Benpine, periodic monitoring is required. This monitoring may include advising blood counts and liver function tests to ensure safety during prolonged use.

How should Benpine be stored and disposed of?

How to Store and Dispose of Benpine

The storage and disposal of Benpine (Chlordiazepoxide) must strictly follow the conditions specified in official regulatory labeling.

Storage Requirements

Benpine must be stored at controlled room temperature, specifically between 20 C to 25 C (68 F to 77 F). The medicine must be kept in its original, tightly closed container and protected from light, moisture, and excessive heat. It is strictly prohibited to freeze the product.

Child-Safety and Disposal

It is mandatory to store Benpine out of the reach of children.

Disposal of unused or expired Benpine should follow official regulatory guidance, prioritizing an approved drug take-back program. If a program is unavailable, the product may be mixed with an undesirable substance, sealed in a container, and placed in the household trash according to federal instructions.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Benpine found in:

A-Z Index: